Allergan Adds Migraine Treatment with purchase of MAP Pharmaceuticals
Allergan today (23/1/13) said that it would buy US based MAP Pharmaceuticals in a $958m acquisition. Allergan is purchasing MAP Pharmaceuticals in cash and has paid a 60% premium on the closing share price of MAP. Allergan expects the deal to dilute 2013 earnings by about 7 cents a share and begin to add revenue in H2 2014. The purchase follows on from a collaboration agreement Allergan and MAP made in January 2011 to co-promote Levadex in the US and Canada.
Genesis 2012 – The Debate on UK Biotech
Authored by Karl Simpson
40 Days Until Rare Disease Day!
Authored by James Sheppard
Liftstream Life Science Newsletter January Edition
The January edition of the newsletter contains:
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Liftstream Celebrates its 9th Anniversary
Parexel Expands Regulatory Capability with Liquent Purchase
On the 27th December 2012, Parexel announced they had completed the purchase of Regulatory Submissions experts Liquent for $72m from Marlin Equity Partners. Liquent is a global provider of Regulatory Information Management solutions to more than 200 biopharmaceutical and life science companies across the globe. Liquent currently have offices based in Pennsylvania (Headquaters), UK, Germany and India. Liquent currently employ nearly 300 staff.
The Resurgence of Gene Therapy
Authored by James Sheppard
